479 related articles for article (PubMed ID: 28468788)
1. Circulating Levels of Proprotein Convertase Subtilisin/Kexin Type 9 and Arterial Stiffness in a Large Population Sample: Data From the Brisighella Heart Study.
Ruscica M; Ferri N; Fogacci F; Rosticci M; Botta M; Marchiano S; Magni P; D'Addato S; Giovannini M; Borghi C; Cicero AFG;
J Am Heart Assoc; 2017 May; 6(5):. PubMed ID: 28468788
[TBL] [Abstract][Full Text] [Related]
2. Plasma PCSK9 levels are unrelated to arterial stiffness in a community-based, 4.8-year prospective study.
Han J; Wang X; Ye P; Cao R; Yang X; Xiao W; Zhang Y; Bai Y; Wu H
J Hum Hypertens; 2017 Nov; 31(11):720-724. PubMed ID: 28816230
[TBL] [Abstract][Full Text] [Related]
3. Plasma proprotein convertase subtilisin/kexin type 9 levels and the risk of first cardiovascular events.
Ridker PM; Rifai N; Bradwin G; Rose L
Eur Heart J; 2016 Feb; 37(6):554-60. PubMed ID: 26508163
[TBL] [Abstract][Full Text] [Related]
4. Circulating proprotein convertase subtilisin-kexin type 9, all-cause mortality, and cardiovascular mortality: The Ludwigshafen Risk and Cardiovascular Health study.
Silbernagel G; Scharnagl H; Kleber ME; Stojakovic T; März W
Eur J Prev Cardiol; 2017 Jul; 24(10):1095-1101. PubMed ID: 28436724
[TBL] [Abstract][Full Text] [Related]
5. Association of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) With Cardiovascular Risk in Primary Prevention.
Zhu YM; Anderson TJ; Sikdar K; Fung M; McQueen MJ; Lonn EM; Verma S
Arterioscler Thromb Vasc Biol; 2015 Oct; 35(10):2254-9. PubMed ID: 26293463
[TBL] [Abstract][Full Text] [Related]
6. Circulating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Predicts Future Risk of Cardiovascular Events Independently of Established Risk Factors.
Leander K; Mälarstig A; Van't Hooft FM; Hyde C; Hellénius ML; Troutt JS; Konrad RJ; Öhrvik J; Hamsten A; de Faire U
Circulation; 2016 Mar; 133(13):1230-9. PubMed ID: 26896437
[TBL] [Abstract][Full Text] [Related]
7. HIV and Hepatitis C-Coinfected Patients Have Lower Low-Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent "PCSK9-Lipid Paradox".
Kohli P; Ganz P; Ma Y; Scherzer R; Hur S; Weigel B; Grunfeld C; Deeks S; Wasserman S; Scott R; Hsue PY
J Am Heart Assoc; 2016 Apr; 5(5):. PubMed ID: 27130349
[TBL] [Abstract][Full Text] [Related]
8. Circulating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Concentration and Risk of Cardiovascular Events - Systematic Review and Meta-Analysis of Prospective Studies.
Xiao Y; Peng C; Huang W; Zhang J; Gao Y; Kim JH; Yeoh EK; Su X
Circ J; 2017 Jul; 81(8):1150-1157. PubMed ID: 28413188
[TBL] [Abstract][Full Text] [Related]
9. [Blood Levels of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Men from Different Population Groups and Its Relation to Unfavorable Long-Term Prognosis].
Ragino YI; Astrakova KS; Shakhtshneider EV; Stakhneva EM; Gafarov VV; Bogatyrev SN; Voevoda MI
Kardiologiia; 2017 Apr; 57(4):72-76. PubMed ID: 28762908
[TBL] [Abstract][Full Text] [Related]
10. Association of serum proprotein convertase subtilisin/kexin type 9 with early atherosclerosis in newly diagnosed type 2 diabetes mellitus.
Guo W; Gong Y; Li J; Qin P; Lu J; Li X; Zhu W; Xu N; Zhou H; Zhang Q
Nutr Metab Cardiovasc Dis; 2019 Aug; 29(8):815-821. PubMed ID: 31133497
[TBL] [Abstract][Full Text] [Related]
11. Serum proprotein convertase subtilisin/Kexin type 9 and vascular disease in type 2 diabetic patients.
Armentaro G; Carbone F; Cassano V; Liberale L; Minetti S; Bertolotto MB; Mannino G; Fiorentino TV; Perticone M; Succurro E; Sesti G; Montecucco F; Andreozzi F; Sciacqua A
Eur J Clin Invest; 2023 Mar; 53(3):e13900. PubMed ID: 36346620
[TBL] [Abstract][Full Text] [Related]
12. Increased sortilin and its independent effect on circulating proprotein convertase subtilisin/kexin type 9 (PCSK9) in statin-naive patients with coronary artery disease.
Hu D; Yang Y; Peng DQ
Int J Cardiol; 2017 Jan; 227():61-65. PubMed ID: 27846466
[TBL] [Abstract][Full Text] [Related]
13. Association between proprotein convertase subtilisin/kexin type 9 and late saphenous vein graft disease after coronary artery bypass grafting: a cross-sectional study.
Gao J; Wang HB; Xiao JY; Ren M; Reilly KH; Li YM; Liu Y
BMJ Open; 2018 Jul; 8(7):e021951. PubMed ID: 29991632
[TBL] [Abstract][Full Text] [Related]
14. Association between circulating proprotein convertase subtilisin/kexin type 9 levels and prognosis in patients with severe chronic kidney disease.
Rasmussen LD; Bøttcher M; Ivarsen P; Jørgensen HS; Nyegaard M; Buttenschøn H; Gustafsen C; Glerup S; Bøtker HE; Svensson M; Winther S
Nephrol Dial Transplant; 2020 Apr; 35(4):632-639. PubMed ID: 30137516
[TBL] [Abstract][Full Text] [Related]
15. Plasma proprotein-convertase-subtilisin/kexin type 9 (PCSK9) and cardiovascular events in type 2 diabetes.
El Khoury P; Roussel R; Fumeron F; Abou-Khalil Y; Velho G; Mohammedi K; Jacob MP; Steg PG; Potier L; Ghaleb Y; Elbitar S; Ragot S; Andreata F; Caligiuri G; Hadjadj S; Boileau C; Marre M; Abifadel M; Varret M; Hansel B
Diabetes Obes Metab; 2018 Apr; 20(4):943-953. PubMed ID: 29205760
[TBL] [Abstract][Full Text] [Related]
16. Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk.
Arsenault BJ; Petrides F; Tabet F; Bao W; Hovingh GK; Boekholdt SM; Ramin-Mangata S; Meilhac O; DeMicco D; Rye KA; Waters DD; Kastelein JJP; Barter P; Lambert G
J Clin Lipidol; 2018; 12(1):130-136. PubMed ID: 29103916
[TBL] [Abstract][Full Text] [Related]
17. Long-term exposure to air pollution raises circulating levels of proprotein convertase subtilisin/kexin type 9 in obese individuals.
Macchi C; Ferri N; Favero C; Cantone L; Vigna L; Pesatori AC; Lupo MG; Sirtori CR; Corsini A; Bollati V; Ruscica M
Eur J Prev Cardiol; 2019 Apr; 26(6):578-588. PubMed ID: 30477320
[TBL] [Abstract][Full Text] [Related]
18. Plasma proprotein convertase subtilisin kexin type 9 levels are related to markers of cholesterol synthesis in familial combined hyperlipidemia.
Brouwers MC; Konrad RJ; van Himbergen TM; Isaacs A; Otokozawa S; Troutt JS; Schaefer EJ; van Greevenbroek MM; Stalenhoef AF; de Graaf J
Nutr Metab Cardiovasc Dis; 2013 Nov; 23(11):1115-21. PubMed ID: 23333725
[TBL] [Abstract][Full Text] [Related]
19. Circulating PCSK9 levels are positively correlated with NMR-assessed atherogenic dyslipidaemia in patients with high cardiovascular risk.
Guardiola M; Plana N; Ibarretxe D; Cabré A; González M; Ribalta J; Masana L
Clin Sci (Lond); 2015 Jun; 128(12):877-82. PubMed ID: 25649668
[TBL] [Abstract][Full Text] [Related]
20. Prediction of cardiovascular events with levels of proprotein convertase subtilisin/kexin type 9: A systematic review and meta-analysis.
Vlachopoulos C; Terentes-Printzios D; Georgiopoulos G; Skoumas I; Koutagiar I; Ioakeimidis N; Stefanadis C; Tousoulis D
Atherosclerosis; 2016 Sep; 252():50-60. PubMed ID: 27501130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
